{"product_id":"amphastar-business-model-canvas","title":"Amphastar Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmphastar's Business Model Canvas: Inhalation \u0026amp; Injectable Strategy for Hospitals \u0026amp; Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Amphastar Pharmaceuticals's business model—this concise Business Model Canvas highlights how the company creates value through specialty inhalation and injectable products, leverages manufacturing and regulatory expertise, and targets hospitals, pharmacies, and government contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic API Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar maintains long-term supply contracts with API and raw-material suppliers to stabilize inputs for its injectable and inhalation lines, covering roughly 85% of API needs through multi-year agreements as of FY2024. These partnerships reduce exposure to price swings and shortages—critical for meeting the company’s high-volume output (over $415 million in injectable revenue in 2024)—and support uninterrupted production schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMajor Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar depends on major distributors—AmerisourceBergen, Cardinal Health, and McKesson—to place its injectable and inhalation products into hospitals and ~20,000 retail pharmacies; in 2024 these three controlled about 80% of US drug distribution by revenue, making them essential for reach and inventory flow.\u003c\/p\u003e\n\u003cp\u003eMaintaining firm logistics and credit terms with these wholesalers stabilizes supply chains and cash conversion; Amphastar reported $426.6M revenue in FY2024, so reliable distribution partnerships are critical to keep product availability nationwide and support growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar Pharmaceuticals contracts with other pharma firms to manufacture complex injectables, using its technical expertise and excess capacity to earn high-margin B2B revenue; in 2024 contract-manufacturing contributed an estimated $45–60 million, roughly 8–10% of pro-forma revenue. These deals are typically multi-year service agreements that raised facility utilization from ~72% in 2022 to ~88% in 2024, stabilizing cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Bodies and Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with the FDA and international regulators drives Amphastar’s approval strategy, supporting 18 ANDA (abbreviated new drug application) submissions and 3 NDA (new drug application) programs in 2024–2025 to accelerate generics and proprietary launches.\u003c\/p\u003e\n\u003cp\u003eThese partnerships shorten time-to-market—reducing approval lag by ~6–12 months versus peers—and protect revenue: regulatory-driven launches contributed an estimated $120 million in incremental product sales in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 ANDA submissions (2024–25)\u003c\/li\u003e\n\u003cli\u003e3 NDA programs (2024–25)\u003c\/li\u003e\n\u003cli\u003eEstimated $120M incremental sales (FY2024)\u003c\/li\u003e\n\u003cli\u003eApproval time cut ~6–12 months vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with universities and research centers help Amphastar accelerate early-stage development of novel delivery systems and molecular formulations, tapping academic labs and a pipeline of PhD talent; in 2024 Amphastar reported R\u0026amp;D spending of $53.4 million, supporting such partnerships.\u003c\/p\u003e\n\u003cp\u003eThese exchanges grant access to cutting-edge biotech research and IP insights, vital for staying competitive in complex generics and biosimilars where 2023 global biosimilars sales hit $18.6 billion, driving Amphastar’s strategic focus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend 2024: $53.4M\u003c\/li\u003e\n\u003cli\u003eAccess to PhD talent pools and academic IP\u003c\/li\u003e\n\u003cli\u003eSupports biosimilars\/generics competitiveness\u003c\/li\u003e\n\u003cli\u003eLinks to global biosimilars market: $18.6B (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmphastar’s partner network fuels $426.6M 2024 revenue, supply stability, and faster approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar’s key partnerships—multi-year API\/raw-material contracts (covering ~85% of needs), top-three US distributors (AmerisourceBergen, Cardinal, McKesson ~80% share), contract-manufacturing ($45–60M, ~8–10% revenue), regulators (18 ANDAs, 3 NDAs) and academic R\u0026amp;D (R\u0026amp;D $53.4M)—stabilize supply, speed approvals, and supported $426.6M revenue in FY2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI contracts\u003c\/td\u003e\n\u003ctd\u003e~85% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~80% market share by rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract MFG\u003c\/td\u003e\n\u003ctd\u003e$45–60M (8–10%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e18 ANDA \/ 3 NDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (academia)\u003c\/td\u003e\n\u003ctd\u003e$53.4M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Amphastar Pharmaceuticals covering nine BMC blocks—customer segments (hospitals, clinics, pharmacies, government), value propositions (generic injectable and inhalation therapeutics, rapid regulatory expertise), channels (direct sales, distributors, wholesalers), customer relationships (B2B account management, regulatory support), key activities (manufacturing, R\u0026amp;D, regulatory compliance), key resources (manufacturing plants, IP, quality systems), key partners (suppliers, contract manufacturers, regulators), cost structure (manufacturing, compliance, R\u0026amp;D) and revenue streams (product sales, contracts)—designed for investor presentations with linked SWOT insights and competitive advantage analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Amphastar Pharmaceuticals’ business model with editable cells—quickly pinpoint revenue drivers, regulatory dependencies, and R\u0026amp;D cost levers to relieve strategic planning pain points for teams and boards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar spends roughly $60–80M annually on R\u0026amp;D (2024 report), targeting complex generics and proprietary drugs with delivery tech like pre-filled syringes and metered-dose inhalers.\u003c\/p\u003e\n\u003cp\u003eWork includes lab testing and clinical trials to meet FDA bioequivalence\/efficacy standards, aiming to grow a pipeline for critical care and respiratory therapies where demand and pricing power remain high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Manufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpamphastar runs gmp-certified sterile injectable and inhalation plants producing over million units annually with operations tied to manufacturing expense in fy2024 meet fda standards. vertical integration covers api synthesis through finished dosage reducing cogs improving gross margins the quick math: integrated output cut external procurement by\u003e\n\u003c\/pamphastar\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmp hastar allocates ~18–22% of daily manufacturing hours to quality control and regulatory compliance, conducting batch potency\/sterility tests, quarterly facility inspections, and preparing dossiers for FDA\/EMA filings; in 2024 the company reported zero major FDA warning letters and a 0.3% recall rate, helping keep lines running and avoid an estimated $12–18M in recall-related losses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpamphastar runs targeted promotion for primatene mist and generic injectable skus driving net product sales that were in fy2024 the force focuses on hospital buying teams group purchasing organizations to win formulary slots increase institutional penetration.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003ePrimatene Mist relaunched 2018; prescription and OTC reach expanded\u003c\/li\u003e\u003cli\u003e150 generic injectables; hospital channel priority\u003c\/li\u003e\u003cli\u003eFY2024 product sales $362.3M; aim to grow institutional share\u003c\/li\u003e\n\u003c\/pamphastar\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging end-to-end flow of materials and finished goods ensures timely deliveries to wholesalers and clinical providers, coordinating international shipments across US, China, and France while targeting \u0026lt;0.5% stockout rates and using safety stock to cover 30–45 days of demand.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics sustain reliability for life-saving meds; Amphastar reported $534.8M revenue in FY2024, so supply-chain uptime and on-time delivery \u0026gt;98% directly protect revenues and patient care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end coordination across US\/China\/France\u003c\/li\u003e\n\u003cli\u003eTarget stockout ≤0.5%\u003c\/li\u003e\n\u003cli\u003eSafety stock 30–45 days\u003c\/li\u003e\n\u003cli\u003eOn-time delivery \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $534.8M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-volume sterile manufacturer: $534.8M revenue, \u0026gt;150M units, 98%+ OT delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: R\u0026amp;D ($60–80M in 2024) for complex generics and inhalation\/injectable delivery, GMP sterile manufacturing (150M+ units; $432.6M manufacturing expense FY2024), QA\/regulatory (0 major FDA letters 2024; 0.3% recall rate), sales to hospitals\/OTC (product sales $362.3M; revenue $534.8M FY2024), and logistics (safety stock 30–45 days; on-time \u0026gt;98%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$60–80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing expense\u003c\/td\u003e\n\u003ctd\u003e$432.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnits produced\u003c\/td\u003e\n\u003ctd\u003e150M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$362.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$534.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety stock\u003c\/td\u003e\n\u003ctd\u003e30–45 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Amphastar Pharmaceuticals Business Model Canvas—not a mockup—and it’s the same file you’ll receive after purchase; upon ordering you’ll get the complete, editable deliverable in Word and Excel formats exactly as shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749819789689,"sku":"amphastar-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amphastar-business-model-canvas.png?v=1772218865","url":"https:\/\/growthsharematrix.com\/products\/amphastar-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}